# Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)

> **NCT03435146** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Aurum Institute NPC** · enrollment: 135 (actual)

## Conditions studied

- Respiratory Tract Infections
- HIV Infections

## Interventions

- **COMBINATION_PRODUCT:** 3HP plus DTG +2NRTIs

## Key facts

- **NCT ID:** NCT03435146
- **Lead sponsor:** The Aurum Institute NPC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-18
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2023-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03435146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03435146, "Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03435146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*